NASDAQ: SNSESensei Biotherapeutics Inc Stock
$0.41-0.01 (-2.38%)
Updated Apr 17, 2025
SNSE Price
$0.41
Fair Value Price
$0.24
Market Cap
$10.23M
52 Week Low
$0.25
52 Week High
$1.94
P/E
-0.34x
P/B
0.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$25M
Beta
1
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SNSE Overview
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNSE's potential to beat the market
- SNSE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SNSE
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SNSE news, forecast changes, insider trades & much more!
SNSE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNSE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNSE ($0.41) is overvalued by 65.84% relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SNSE ($0.41) is not significantly undervalued (65.84%) relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNSE due diligence checks available for Premium users.
Valuation
SNSE fair value
Fair Value of SNSE stock based on Discounted Cash Flow (DCF)
Price
$0.41
Fair Value
$0.24
Overvalued by
67.48%
SNSE ($0.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNSE ($0.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNSE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.34x
Industry
-177.72x
Market
27.98x
SNSE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.27x
Industry
4.05x
SNSE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNSE's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.8M
Profit Margin
0%
SNSE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$45.4M
Liabilities
$7.0M
Debt to equity
0.18
SNSE's short-term assets ($41.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNSE's short-term assets ($41.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNSE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNSE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.8M
Investing
-$3.2M
Financing
-$194.0k
SNSE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNSE vs Biotech Stocks
Sensei Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.